Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health claims debate

This article was originally published in The Tan Sheet

Executive Summary

Firms value authorized health claims "much more" than qualified claims "and will always prefer an authorized claim to an unauthorized one and only thereafter an unauthorized one to none at all," supplement marketers say in July 1 comments to FDA. Filed on behalf of Life Extension Foundation and Julian Whitaker, MD, by Washington, D.C-based Emord & Associates, comments respond to CSPI assertions that qualified claims eliminate incentive for authorized claims. On the contrary, the "two-tiered claim approach has the effect of encouraging research because rather than an all-or-nothing [significant scientific agreement] option, the fact that a qualified claim exists affords enough security to justify risking capital," comments state. Firms also maintain CSPI, in criticizing health claims, ignores Pearson rulings forcing FDA to favor disclaimers over speech suppression. CSPI filed comments in June (1"The Tan Sheet" June 9, 2003, p. 16)...

You may also be interested in...



Focus Group Testing For Health Claim Consumer Perception Advised By CSPI

FDA should use focus groups to determine whether consumers understand or are misled by health claims on foods and dietary supplements, according to comments submitted to FDA June 4 by the Center for Science in the Public Interest

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Topics

UsernamePublicRestriction

Register

PS095656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel